Mode
Text Size
Log in / Sign up
Phase 3 N=419 Treatment

Mobile - Bearing Knee Study

Inflammatory Tissue Disorder · Osteoarthritis · Avascular Necrosis · Post-traumatic Arthritis · Secondary Arthritis

Enrolled (actual)
419
Serious AEs
0.0%
Results posted
Apr 2011
Primary outcome: Primary: Knee Society Score Evaluation — 93.1 Average Knee Rating Score

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Encore Mobile-Bearing Knee (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Encore Medical, L.P.
Primary completion
Jun 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
Knee Society Score Evaluation
93.1
PRIMARY
Knee Society Function Score
89.0
PRIMARY
Knee Society Scores Used as Success/Failure Criteria.
91; 84

Summary

To evaluate the safety and efficacy of the Encore Mobile-Bearing Knee.

Eligibility Criteria

Inclusion Criteria

  • Skeletal maturity
  • Less than 70 on preoperative Knee Society Score (Rating Score)
  • Sufficient bone stock, as judged by radiographs, to support primary knee implant
  • Patients with inflammatory tissue disorders, osteoarthritis, post-traumatic arthritis, secondary arthritis, or avascular necrosis of the femoral condyles
  • Patient is not pregnant
  • Primary total knee replacement
  • Sufficient collateral ligaments to support device, as judged by physician during stability testing (varus/valgus and flexion/extension)
  • Varus deformity 45 or valgus deformity >45 or fixed flexion deformity >90.
  • Mental conditions that may interfere with ability to give an informed consent or willingness to fulfill the study requirements (i.e., severe mental retardation such that the patient cannot understand the informed consent process, global dementia, prior strokes that interfere the with patient's cognitive abilities, senile dementia, and Alzheimer's Disease).
  • Prisoners
  • Conditions that place excessive demand on the implant (i.e. Charcot's joints, muscle deficiencies, refusal to modify postoperative physical activities, skeletal immaturity).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00765362). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search